Medizinische Fakul­tät OWL

Attention-Deficit/Hyperactivity Disorder (ADHD) is frequently overlooked or misdiagnosed in individuals with intellectual disabilities (ID). Conventional diagnostic methods, such as self-reports and external assessments, often fail in this population due to cognitive limitations, communication barriers, and overlapping symptoms with other conditions. As a result, many individuals remain undiagnosed or receive inappropriate treatment, leading to significant challenges in daily life, including difficulties in education, employment, and social interactions. In many cases, overmedication is a common consequence of misdiagnosis, further impacting overall well-being.

To address these challenges, GAZE-AID is developing an innovative, technology-driven approach to ADHD diagnosis. A collaboration between the University Clinic for Inclusive Medicine and the AG Medical Assistance Systems, this research project aims to integrate gaze-tracking technology into the diagnostic process. Unlike conventional methods, gaze tracking provides an objective and non-invasive way to measure attention patterns and executive functions, eliminating reliance on verbal communication or subjective assessments. Research in individuals without ID has already shown that gaze-tracking significantly improves diagnostic accuracy, and GAZE-AID is adapting this approach specifically for individuals with ID.

Our goal is to create a diagnostic tool that is precise, accessible, and tailored to the needs of individuals with ID. By offering a more reliable method to assess ADHD symptoms, GAZE-AID can enable more targeted treatments, reduce the risk of overmedication, and ultimately enhance the quality of life for those affected. In the long term, our research could pave the way for broader applications of gaze-tracking technology in neurodevelopmental and psychiatric disorders, improving diagnostic standards and individualized care.

With GAZE-AID, we are taking a step toward a more inclusive and accurate ADHD diagnosis, ensuring that individuals with ID receive the support and treatment they truly need.